Huaren Pharmaceutical Co., Ltd. (SHE:300110)

China flag China · Delayed Price · Currency is CNY
3.150
0.00 (0.00%)
Apr 30, 2026, 3:04 PM CST
8.62%
Market Cap 3.72B
Revenue (ttm) 1.33B
Net Income (ttm) -462.97M
Shares Out 1.18B
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,756,520
Average Volume 46,347,268
Open 3.050
Previous Close 3.150
Day's Range 3.050 - 3.200
52-Week Range 2.820 - 3.750
Beta 0.42
RSI 48.14
Earnings Date Apr 24, 2026

About Huaren Pharmaceutical

Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, ant... [Read more]

Sector Healthcare
Founded 1998
Employees 2,491
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300110
Full Company Profile

Financial Performance

In 2025, Huaren Pharmaceutical's revenue was 1.32 billion, a decrease of -2.34% compared to the previous year's 1.35 billion. Losses were -462.90 million, -66.17% less than in 2024.

Financial Statements

News

There is no news available yet.